Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05766800 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria revisedv5
  2. Interventions: Carboplatin (Drug), Nab-paclitaxel (Drug), Pemetrexed (Drug), Radiotherapy (Radiation), Serplulimab (Drug), Surgery (Procedure) to Carboplatin (Drug), Liposomal paclitaxel (Drug), Nab-paclitaxel (Drug), Pemetrexed (Drug), Radiotherapy (Radiation), Serplulimab (Drug)…v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 13, 2023 to Mar 14, 2023
    v3
  4. Start date: Mar 1, 2023 to Mar 13, 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
For unresectable locally-advanced non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery.
Trial Details
NCT Number NCT05766800
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions
(from sponsor)		 Locally Advanced, Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov